This poster, presented at AAN 2025, assesses the reliability of ataluren effectiveness in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) in the STRIDE Registry, and determines whether genetic mutation is a source of bias
American Academy of Neurology Annual Meeting (AAN)
The American Academy of Neurology (AAN) Annual Meeting is the world’s largest conference for neurology and neuroscience professionals.
Please select the resource of interest below:
|
Congress
Topic
Type
Year
Access PTC abstracts, infographics, posters and symposia presented at international meetings in the fields of pediatric neurology, cognitive neuroscience and movement disorders, such as the Muscular Dystrophy Association (MDA) Annual Clinical & Scientific Conference, the Child Neurological Society (CNS) Annual Meeting, the World Muscle Society (WMS) Annual Congress, and International Congress on Neuromuscular Diseases (ICNMD).
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-ATLN-2500006 | September 2025
Registration conditions vary by country; please consult local prescribing information and/or the Summary of Product Characteristics prior to prescribing any products.
MED-ALL-DFZ-2500002 v-2 | April 2026
MED-ALL-DMD-2200043 | June 2025